Simply Wall St.1d agoneutral
Iovance Biotherapeutics (IOVA) Q3 Earnings Sharpen Focus On Margin RecoveryNews
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
107last 24h
3127last 7d
512● bullish (7d)
311● bearish (7d)
227publishers
GuruFocus.com2d agoneutral
Iovance Biotherapeutics Inc (IOVA) (Q3 2026) Earnings Call Highlights: Record $122 Million ...Simply Wall St.3d agobullish
Iovance Biotherapeutics (IOVA) Lifileucel Wins Fast Track After Strong Sarcoma Trial DataMT Newswires5d agoneutral
UBS Adjusts Price Target on Iovance Biotherapeutics to $8 From $7, Maintains Neutral RatingInvestor's Business Daily9d agobearish
Iovance, A Top 1% Biotech Stock, Crashes In A Surprise Lung Cancer TwistSimply Wall St.9d agoneutral
Iovance Biotherapeutics (IOVA) Posts 59.1% Response In Lifileucel Lung Cancer Study